HLA-Associated Clinical Progression Correlates with Epitope Reversion Rates in Early Human Immunodeficiency Virus Infection

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) can evade immunity shortly after transmission to a new host but the clinical significance of this early viral adaptation in HIV infection is not clear. We present an analysis of sequence variation from a longitudinal cohort study of HIV adaptation in 189 acute seroconverters followed for up to 3 years. We measured the rates of variation within well-defined epitopes to determine associations with the HLA-linked hazard of disease progression. We found early reversion across both the gag and pol genes, with a 10-fold faster rate of escape in gag (2.2 versus 0.27 forward mutations/1,000 amino acid sites). For most epitopes (23/34), variation in the HLA-matched and HLA-unmatched controls was similar. For a minority of epitopes (8/34, and generally associated with HLA class I alleles that confer clinical benefit), new variants appeared early and consistently over the first 3 years of infection. Reversion occurred early at a rate which was HLA-dependent and correlated with the HLA class 1-associated relative hazard of disease progression and death (P = 0.0008), reinforcing the association between strong cytotoxic T-lymphocyte responses, viral fitness, and disease status. These data provide a comprehensive overview of viral adaptation in the first 3 years of infection. Our findings of HLA-dependent reversion suggest that costs are borne by some escape variants which may benefit the host, a finding contrary to a simple immune evasion paradigm. These epitopes, which are both strongly and frequently recognized, and for which escape involves a high cost to the virus, have the potential to optimize vaccine design.

[1]  David Heckerman,et al.  Marked Epitope- and Allele-Specific Differences in Rates of Mutation in Human Immunodeficiency Type 1 (HIV-1) Gag, Pol, and Nef Cytotoxic T-Lymphocyte Epitopes in Acute/Early HIV-1 Infection , 2008, Journal of Virology.

[2]  D. Heckerman,et al.  Central Role of Reverting Mutations in HLA Associations with Human Immunodeficiency Virus Set Point , 2008, Journal of Virology.

[3]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[4]  Tanmoy Bhattacharya,et al.  HLA Class I-Driven Evolution of Human Immunodeficiency Virus Type 1 Subtype C Proteome: Immune Escape and Viral Load , 2008, Journal of Virology.

[5]  R. Weiss.  Special Anniversary Review: Twenty-five years of human immunodeficiency virus research: successes and challenges , 2008, Clinical and experimental immunology.

[6]  David A. Price,et al.  Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover , 2007, The Journal of experimental medicine.

[7]  David Heckerman,et al.  Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1 , 2007, PLoS pathogens.

[8]  N. Pantazis,et al.  Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort , 2007, AIDS.

[9]  Becca Asquith,et al.  In vivo CD8+ T cell control of immunodeficiency virus infection in humans and macaques , 2007, Proceedings of the National Academy of Sciences.

[10]  B. Walker,et al.  Effective T-Cell Responses Select Human Immunodeficiency Virus Mutants and Slow Disease Progression , 2007, Journal of Virology.

[11]  D. Heckerman,et al.  Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations , 2007, Science.

[12]  Bin Li,et al.  Rapid Reversion of Sequence Polymorphisms Dominates Early Human Immunodeficiency Virus Type 1 Evolution , 2006, Journal of Virology.

[13]  Todd M. Allen,et al.  HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8+ T Cell Response against HIV-1 , 2006, PLoS medicine.

[14]  E. Holmes,et al.  Passive Sexual Transmission of Human Immunodeficiency Virus Type 1 Variants and Adaptation in New Hosts , 2006, Journal of Virology.

[15]  Mario Roederer,et al.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.

[16]  D. Cornforth,et al.  HIV-1 Epitope-Specific CD8+ T Cell Responses Strongly Associated with Delayed Disease Progression Cross-Recognize Epitope Variants Efficiently1 , 2006, The Journal of Immunology.

[17]  B. Walker,et al.  Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[18]  Becca Asquith,et al.  Inefficient Cytotoxic T Lymphocyte–Mediated Killing of HIV-1–Infected Cells In Vivo , 2006, PLoS biology.

[19]  J. Goedert,et al.  AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis , 2005, Nature Medicine.

[20]  Andrew K. Sewell,et al.  Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA , 2005, The Journal of experimental medicine.

[21]  Bette Korber,et al.  Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA , 2004, Nature.

[22]  Bernard Hirschel,et al.  Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  B. Walker,et al.  Immune Escape Precedes Breakthrough Human Immunodeficiency Virus Type 1 Viremia and Broadening of the Cytotoxic T-Lymphocyte Response in an HLA-B27-Positive Long-Term-Nonprogressing Child , 2004, Journal of Virology.

[24]  G. M. Ortiz,et al.  Relevance of HIV-1-Specific CD4+ Helper T-Cell Responses During Structured Treatment Interruptions in Patients With CD4+ T-Cell Nadir Above 400/mm3 , 2004, Journal of acquired immune deficiency syndromes.

[25]  E. Rosenberg,et al.  Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  D. Strick,et al.  Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses Directed against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but No Correlation to Viral Load , 2003, Journal of Virology.

[27]  A. Oxenius,et al.  Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection , 2002, AIDS.

[28]  H. Günthard,et al.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Klenerman,et al.  HIV: current opinion in escapology. , 2002, Current opinion in microbiology.

[30]  C. Moore,et al.  Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Level , 2002, Science.

[31]  M. Carrington,et al.  HLA and AIDS: a cautionary tale. , 2001, Trends in molecular medicine.

[32]  J J Goedert,et al.  Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. , 2001, The New England journal of medicine.

[33]  Edward C. Holmes,et al.  Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27–Restricted Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[34]  S. Osmanov,et al.  Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. , 2000, AIDS research and human retroviruses.

[35]  S. Rowland-Jones,et al.  Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection , 2000, AIDS.

[36]  B. Walker,et al.  Lack of Viral Escape and Defective In Vivo Activation of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes in Rapidly Progressive Infection , 1999, Journal of Virology.

[37]  J. Goedert,et al.  HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. , 1999, Science.

[38]  S. Oka,et al.  Identification of multiple HIV-1 CTL epitopes presented by HLA-B*5101 molecules. , 1999, Human immunology.

[39]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[40]  S. Oka,et al.  Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS. , 1997, Journal of immunology.

[41]  Martin A. Nowak,et al.  Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS , 1997, Nature Medicine.

[42]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[43]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[44]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[45]  David Heckerman,et al.  CD8+ T-cell responses to different HIV proteins have discordant associations with viral load , 2007, Nature Medicine.

[46]  E. Domingo,et al.  Cytotoxic T-lymphocyte responses to HIV-1 reverse transcriptase (review). , 1998, Viral immunology.

[47]  Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. , 1987, MMWR supplements.